Results 91 to 100 of about 1,442,499 (293)

Notes: Emetics, No. 1

open access: yes, 1880
Dr. Porcher's handwritten notebook on emetics. Preferred citation: Francis Peyre Porcher Papers, MSS 299, Waring Historical Library, Medical University of South Carolina ...
Porcher, Francis Peyre (1824 - 1895)
core  

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton   +8 more
wiley   +1 more source

Hematuria: A rare presentation of G6PD deficiency

open access: yesGomal Journal of Medical Sciences, 2004
A young man presented to urologist with a history of passing red color urine after intake of some medications from the local doctor. On investigations he was having anemia, altered liver function tests, mild renal impairment, and evidence of hemolysis ...
Muhammad Anees   +5 more
doaj  

Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy

open access: yesJournal of the Egyptian National Cancer Institute, 2017
Background: Neurokinin-1 receptor antagonists, such as aprepitant are currently emerging as powerful prophylactic agents for chemotherapy-induced nausea and vomiting (CINV).
Raafat Abdel-Malek   +6 more
doaj   +1 more source

Christian Anti-Communism Crusade - Application for membership

open access: yes, 1962
Christian Anti-Communism Crusade - Application for ...
Christian Anti-Communism Crusade
core  

What works for whom in school-based anti-bullying interventions? An individual participant data meta-analysis

open access: yes, 2023
: The prevalence of bullying worldwide is high (UNESCO, 2018). Over the past decades, many anti-bullying interventions have been developed to remediate this problem.
Kuijper, Steven C.   +6 more
core  

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo   +12 more
wiley   +1 more source

Notes: Emetics, No. 2 & 3

open access: yes, 1880
Dr. Porcher's handwritten notebook on emetics. Preferred citation: Francis Peyre Porcher Papers, MSS 299, Waring Historical Library, Medical University of South Carolina ...
Porcher, Francis Peyre (1824 - 1895)
core  

Smoldering Systemic Mastocytosis Without Detectable KIT Mutation: A Debilitating Course and Therapeutic Challenge

open access: yesCancer Nexus, EarlyView.
Graphical abstract illustrating the clinical course and treatment response. ABSTRACT Systemic mastocytosis (SM) is a clonal hematologic neoplasm driven by activating KIT mutations, particularly D816V. Indolent SM typically follows a stable course, progression to higher‐burden subtypes is uncommon.
Homeniuk Anna   +5 more
wiley   +1 more source

Anti-dumping Policy and Anti-dumping Retaliation

open access: yes, 2016
This paper analyzes the incentives to petition for anti-dumping protection in the context of anti-dumping retaliation. We examine how anti-dumping retaliation may arise and whether such retaliation can be a threat that dissuades a domestic firm facing ...
Chen, Chin-Sheng;Kao, Kuo-Feng   +1 more
core  

Home - About - Disclaimer - Privacy